We use advanced technology to identify the genetic variants in patients' genomes involved in the disease being treated. It is essential to offer personalised treatment. This technology allows us to detect any variants related to heredity and therefore determine susceptibility to a disease. This enables risk elimination, disease prevention or early diagnosis.
We offer genetic counselling
We know that making information on hereditary diseases available affects families emotionally, which is why we rely on specific genetic counselling to assess and address the effects this has.
We cooperate and do research with international centres
We are in touch with professionals from other national and international centres, and we actively take part in different research projects. Our physicians and investigators belong to the U703 and U732 units of the CIBER on Rare Diseases (CIBERER); the TREAT-CMT study of Charcot-Marie-Tooth disease, funded by Instituto de Salud Carlos III within the IRDiRC's international framework; and the EFACTS study of Friedreich's ataxia, funded by the European Commission's 7th Framework Programme, amongst others.